- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01579721
Prospective Randomized Study of SILS Versus CLS for Rectal Cancer
Prospective Randomized Study of Single Incision Laparoscopic Surgery Versus Conventional Laparoscopic Surgery for Rectal Cancer
Background: Single-port laparoscopic surgery is emerging as a method to improve morbidity and cosmetic benefits of conventional laparoscopic surgery and minimize the surgical trauma. However, the feasibility of this procedure in rectal surgery has not been determined yet. The aim of this study is to evaluate our initial experience using single port access in laparoscopic rectal surgery.
Design: randomized, prospective clinical study Patients: 40 patients
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Hvidovre, Denmark, DK-2650
- Department of Gastroentestinal Surgery, Hvidovre Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients > 18 years of age.
- ASA I-III.
- Tumor-location: maximum 15 cm from the anal verge.
- No involvement of neighbouring organs.
- No distant metastasis.
Exclusion Criteria:
- Linguistic, physical or psychological barriers precluding oral and written consent.
- History of intestinal surgery (excl. appendectomy).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: SILS-group
20 patients undergoing Single Incision Laparoscopic Surgery
|
Single incision laparoscopic surgery for rectal cancer
|
|
No Intervention: CLS-group
20 patients undergoing Conventional Laparoscopic Surgery for rectal cancer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
morbidity
Time Frame: 30 days
|
The purpose of this study is to compare 30-days postoperative morbidity between the two groups
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
immunology
Time Frame: 72 hours postoperatively
|
to compare results of blood-samples (C-reactive protein, leucocyte-count and interleukin-6) 72 hours postoperatively between the two groups
|
72 hours postoperatively
|
|
postoperative outcome
Time Frame: 5 days postoperatively
|
to compare postoperative results (postoperative pain, time to bowel function, time to regain full diet and mobilisation) between the two groups.
|
5 days postoperatively
|
|
oncology
Time Frame: 30 days
|
Comparison of the oncological results (quality of specimen, completeness of mesorectal fascia, circumferential resection margin, number of harvested lymphnodes, TNM-classification) between the two groups.
|
30 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SILS rectal cancer
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma
-
Yale UniversityRecruitingGastric Adenocarcinoma | Pancreas Adenocarcinoma | Gastroesophageal Adenocarcinoma | Esophageal Adenocarcinoma | Ampullary Adenocarcinoma | Gallbladder Adenocarcinoma | Duodenal Adenocarcinoma | Foregut Adenocarcinoma | Intra - and Extrahepatic CholangiocarcinomaUnited States
-
UMC UtrechtJulius Centre for Health Sciences and Primary Care, UMC UtrechtRecruitingEsophageal Adenocarcinoma | Esophageal Adenocarcinoma (EAC) | Adenocarcinoma - Gastroesophageal Junction (GEJ)Netherlands
-
Criterium, Inc.University of Colorado, Denver; NovartisTerminatedPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Cholangiocarcinoma | Esophageal Adenocarcinoma | Colorectal Adenocarcinoma | Hepatocellular AdenocarcinomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Not yet recruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States
-
Gilead SciencesRecruitingGastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction | HER2-negativeAustralia
-
Abramson Cancer Center at Penn MedicineReplimune, Inc.Not yet recruitingGastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States
-
Weill Medical College of Cornell UniversityMerck Sharp & Dohme LLC; Oncolys BioPharma IncRecruitingGastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States
-
European Institute of OncologyRecruitingGastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaItaly
-
University of ChicagoTerminatedGastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States
-
Roswell Park Cancer InstituteUnited States Department of DefenseRecruitingClinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction... and other conditionsUnited States
Clinical Trials on Single Incision Laparoscopic Surgery
-
Ruijin HospitalCompleted
-
University of California, San DiegoCompletedAppendicitis | Cholelithiasis | Malignant HypertensionUnited States
-
Guoxin LiUnknown
-
University of Texas Southwestern Medical CenterCompleted
-
Ruijin HospitalChanghai Hospital; Fudan University; RenJi Hospital; Shengjing Hospital; Shandong... and other collaboratorsRecruitingColorectal Cancer | Rectal Cancer | Colon CancerChina
-
Ruijin HospitalChanghai Hospital; Fudan University; RenJi HospitalWithdrawnRectal Diseases | Colorectal Cancer | Rectal Cancer | Rectal Neoplasms | Colon Cancer | Colonic Neoplasms | Colon DiseaseChina
-
Fujian Cancer HospitalRecruiting
-
Saint Luke's Health SystemTyco Healthcare Group LP (d/b/a Covidien)TerminatedCholecystitis | Biliary Dyskinesia | Gallstones | CholelithiasisUnited States
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityThe First Affiliated Hospital of Nanchang University; West China Hospital; Hubei... and other collaboratorsNot yet recruiting
-
Hospital PlatóCompleted